Showing results (221-230 of 899) with videos related to
Sort By:
Pageof 90
Presse Medicale (Paris, France : 1983)|September 2, 2019
[The Childhood Asthma Control Test improves the therapeutic adaptations recommended for asthmatics aged 6 to 11 years in primary practice. A Randomized comparative prospective study]Guillaume Perron, Marc Garcia, François Carbonnel, et al.Clinical and Translational Allergy|April 24, 2015
Categorization of allergic disorders in the new World Health Organization International Classification of DiseasesLuciana Kase Tanno, Moises A Calderon, Bruce J Goldberg, et al.Clinical and Translational Allergy|July 31, 2014
An EAACI "European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": the methodologyMoises A Calderón, Pablo Rodríguez Del Río, Carmen Vidal, et al.Allergy|December 28, 2018
Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in FrancePhilippe Devillier, Mathieu Molimard, Xavier Ansolabehere, et al.Orphanet Journal of Rare Diseases|January 15, 2017
Fatal anaphylaxis registries data support changes in the who anaphylaxis mortality coding rulesLuciana Kase Tanno, F Estelle R Simons, Isabella Annesi-Maesano, et al.Journal of Ophthalmology|October 10, 2022
New Keratoconus Risk Factors: A Cross-Sectional Case-Control StudyEloi Debourdeau, Gabriel Planells, Chloe Chamard, et al.American Journal of Rhinology & Allergy|September 9, 2014
Prevalence of uncontrolled allergic rhinitis in Wuhan, China: a prospective cohort studyYouna Wang, Rongfei Zhu, Guanghui Liu, et al.The Journal of Allergy and Clinical Immunology. in Practice|January 1, 2021
Cephalosporin Hypersensitivity: Descriptive Analysis, Cross-Reactivity, and Risk FactorsNidhal Touati, Barbara Cardoso, Marie Delpuech, et al.Allergy|March 27, 2023
Adherence and persistence in allergen immunotherapy (APAIT): A reporting checklist for retrospective studiesOliver Pfaar, Philippe Devillier, Jochen Schmitt, et al.The World Allergy Organization Journal|July 22, 2024
Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing dataMargitta Worm, Pascal Demoly, Yoshitaka Okamoto, et al.Pageof 90